clinical trials |
News, Publications, and Related Stories
Los Angeles Times -- March 22, 2010 Dr. Donald Hensrud, an associate professor of preventive medicine and nutrition. View Related 
Novel method speeds analysis for individualized medicine Mayo Clinic researchers along with collaborators from Life Technologies are reporting on the application of a new approach for sequencing RNA to study cancer tumors. View Related 
Med Page Today -- Dec. 22, 2009 Edith Perez, M.D., Mayo Clinic, Jacksonville, Fla., comments on the study results. View Related 
Renal & Urology News -- Dec. 17, 2009 Researchers at Mayo Clinic in Phoenix have reported a promising early experience with performing extraperitoneal robot-assisted radical prostatectomy (RARP) procedures on an outpatient basis. View Related 
Tehran Times -- Dec. 12, 2009 Lead investigator: Jan van Deursen, Ph.D., Mayo Clinic in Rochester, Minn. View Related 
Los Angeles Times -- Dec. 12, 2009 Lead researcher: Edith Perez, M.D., Mayo Clinic in Jacksonville, Fla. View Related 
U.S. News and World Report -- Dec. 7, 2009 Mayo Clinic endocrinologist Matthew Drake, M.D., Ph.D., presented the findings at the Dec. 5 meeting of the American Society of Hematology. View Related 
Wall Street Journal -- Nov. 19, 2009 Sandhya Pruthi, M.D., director of Mayo Clinic Breast Clinic, Rochester, Minn., answers questions related to these new guidelines. View Related 
Mayo task force says women 40 and older should be screened as per usual Mayo Clinic will continue to recommend screening mammograms for women age 40 and older. "Everyday we discover invasive breast cancer in a woman age 40–50," says Sandhya Pruthi, M.D., director of the Breast Clinic at Mayo Clinic in Rochester, and leader of the task force. View Related
Co-Leaders of Two Cancer Center Programs Were Among Those Honored Cancer Center recipients are Charles Loprinzi, M.D., co-leader of the Cancer Prevention and Control Program and Rafael Fonseca, M.D., co-leader of the Hematologic Malignancies Program. View Related
The study suggests that if a man's PSA level is rising quickly, a prostate biopsy is reasonable to determine if he has prostate cancer. Additional audio and video resources are available on the Mayo Clinic News Blog. View Related 
High-definition (HD) colonoscopy is much more sensitive than standard colonoscopy in finding polyps that could morph into cancer, say researchers at the Mayo Clinic campus in Florida. View Related 
The team's findings were presented Oct. 28, 2009, at the annual meeting of the American College of Gastroenterology in San Diego. View Related 
A diagnosis of Barrett's esophagus can be concerning because it increases the risk of developing esophageal cancer. View Related 
The Daily Scan, genomeweb.com -- Oct. 26, 2009 Research by Stephen Ekker, Ph.D., et al, regarding genetic differences in response to nicotine, using zebrafish animal model View Abstract 
Mayo Clinic Study Shows People with Heart Devices Can 'Digest' Advanced Diagnostic Technology Safely
Capsule endoscopy risk appears minimal in largest study to date View Related 
Discovery's Edge - Mayo Clinic's Research Publication Zebrafish make an ideal model organism for genetic and developmental studies. A molecular biologist at Mayo is not only using the fish to investigate new treatments for cancer and nicotine addiction, but also as the foundation of a paradigm to get students excited about science. View Related 
National Cancer Institute (NCI) Cancer Bulletin -- Oct. 6, 2009 Mayo Clinic's Julian Molina, M.D., Ph.D., was among 11 honored. View Related
Researchers say this method is more accurate in predicting risk for an individual than the Gail model. View Abstract 
Discovery's Edge - Mayo's Research Publication What causes brain tumors? Using statistics from Mayo’s enormous patient databases, genetics researchers are learning how genetic mutations and environmental triggers increase the risk of developing brain cancer. View Related 
Publication: Cancer Research -- Sept. 29, 2009 
Researchers say the findings from Mayo Clinic's campuses in Florida and Minnesota suggest that patients and their physicians should not overly worry about toxicity and side effects from the treatment, known as salvage external beam radiotherapy. View Related 
Mayo Clinic Performs Groundbreaking, Single-incision Surgery to Remove Young Woman's Large Intestine
This operation was recommended to the patient because of a diagnosis of familial adenomatous polyposis. Without surgical removal of the colon and rectum, the risk of developing colorectal cancer is 100 percent. View Related 
Event: Rochester, Minn. 
According to the American Cancer Society, lung cancer is the second most common cancer among both men and women, and the leading cause of cancer death in the United States. "Lung cancer stem cells appear to be the major drivers in many common lung cancers, and in order for a therapeutic treatment to be effective, it has to disrupt these cancer stem cells," says study senior author Alan Fields, Ph.D., professor of pharmacology and chair of the Department of Cancer Biology at Mayo Clinic's campus in Florida. "We show that aurothiomalate, the agent now being tested in lung cancer patients, can, in fact, target these cells." View Related
Publication: The Journal of Clinical Investigation -- September 2009 
Publication: Mayo Clinic Proceedings -- Sept. 2009 See video interview with Gordon W. Dewald, Ph.D. View Related 
It is the seventh SPORE grant that Mayo has received to support cancer research. "The Mayo Ovarian Cancer SPORE is uniquely poised to address key challenges in ovarian cancer," says Lynn Hartmann, M.D., lead investigator of the newly awarded SPORE. "Our balance of basic, population science and clinical research programs within the Mayo Clinic Cancer Center enables us to pursue major issues in ovarian cancer, such as chemotherapy resistance, and quickly move new approaches into the clinic." View Related 
Cancer Center member Jan van Deursen, Ph.D. was awarded the Vita Valley Professorship in Cellular Senescence. View Related 
Orland Park Prairie: Aug. 12, 2009 "Mayo Clinic received $15,000 and will use the funds for a database that will help bring new therapies by streamlining access to stored tissue samples." View Related 
Publication: Mayo Clinic Proceedings -- Aug. 2009 See video interview with S. Vincent Rajkumar, M.D. View Related 
PCNSL most often affects the elderly, people who are immunosuppressed because of illness or transplant, and patients with AIDS. Though uncommon, this tumor is increasing in incidence, even in patients without known risk factors. View Abstract 
Offering cancer patients in Florida and the Southeast access to investigational therapies through rigorously monitored clinical trials "The cancer field is rapidly moving to use of these new agents as a way to improve upon the success we have seen with more traditional therapies, such as chemotherapy and radiation," says says Michael Menefee, M.D., who heads the Phase I Clinical Trial Program in Oncology at Mayo Clinic, Jacksonville. View Related 
Bret Friday, M.D., of the Duluth, Minn., membership will work with Mayo Clinic and other NCCTG researchers in the development and conduct of neuro-oncology clinical trials View Related
Mayo Clinic Cancer Center receives an additional five years of National Cancer Institute (NCI) funding and re-designation as a comprehensive cancer center.
Mayo Clinic researchers and colleagues at the University of California San Francisco (UCSF) have found a connection between DNA alterations on human chromosome 9 and aggressive brain cancer known as glioblastoma. The findings are reported in the current online issue of Nature Genetics. View Abstract 
Publication: Blood -- June 26, 2009 International Myeloma Working Group recommendations View Related
Surgery involved removal of entire colon and joining small bowel to rectum A 32-year-old woman from Maricopa, Ariz., who was at risk for colon cancer, is believed to be the first patient in the U.S. to undergo single-incision total colectomy — an operation in which in the entire colon is removed. View Related 
Multi-center study co-authored by Mayo Clinic reveals promising treatment Dysplastic, or pre-cancerous lesions, can lead to esophageal cancer. Radiofrequency ablation is a procedure that uses high-intensity radio waves to zap the lesions. View Related
A 76-year-old Scottsdale, Ariz., man is the 100th patient at Mayo Clinic to receive an allogeneic stem cell transplant since the program began in 2003. View Related
Most people associate colorectal cancer screening with invasive colonoscopy, but previous Mayo Clinic research has shown that stool DNA testing can identify both early-stage colorectal cancer and precancerous polyps. View Related 
Pancreatic cancer and bile duct cancer are difficult to diagnose and often fatal because they are discovered in the advanced stages of the disease. View Related 
Medical Edge Newspaper -- Read Column I am a 68-year-old man in relatively good health. I am an ex-smoker, but quit the habit years ago. Last week I was diagnosed with early stage bladder cancer. Is it true that my smoking could have caused this? How serious is bladder cancer? What are the latest treatment options? View Related 
Study findings presented Saturday, May 30, at the American Society of Clinical Oncology annual meeting in Orlando. View Abstract 
"[Advancing the Science] is aimed at the public, but the topic is how medical science improves patient care," says blog editor Bob Nellis of Mayo's Public Affairs Department. View Related 
Medical Edge Newspaper -- Read Column My uncle has been diagnosed with melanoma, but the tumor is internal with no sign of external lesions. This is the second case I have heard of like this. Is this getting more common? What can be done? View Related
In the May 15 issue of Cancer, Mayo researchers showed that the levels of three proteins (survivin, B7-H1, ki-67) in ccRCC tumor tissue can be used to predict which patients will ultimately die from their cancer. View Abstract 
Presented at the American Society of Clinical Oncology (ASCO) "The benefits were striking in many patients to a degree we have not previously seen in thyroid cancer in response to other therapies, including the standard treatment of radioiodine," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial funded by the National Cancer Institute. View Abstract 
Presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO). A combination of capecitabine, vinorelbine, and trastuzumab offers a treatment option that is at least as beneficial as other current options — and doesn't cause hair loss in patients. View Abstract 
Presented at the annual meeting of the American Association for Cancer Research (AACR). View Related 
Presented at the American Association for Cancer Research (AACR). The finding is particularly significant, says the study's first author, Mamta Gupta, Ph.D., because the three cell lines studied were all resistant to the effects of chemotherapy - as are many pancreatic tumors - and because the drugs studied are already available for treatment of patients. View Related
Researchers say that a molecule known as protein kinase D1 (PKD1) is key to the ability of a tumor cell to "remodel" its structure, enabling it to migrate and invade. View Abstract
Expression of immunosuppresive B7-H3 ligand by hormone-treated prostate cancer tumors and metastases
Publication: Clinical Cancer Research -- Mar. 15, 2009 View Related
Ablation technique shown effective for patients with high and low-grade dysplasia 
Robotic surgery for the treatment of tonsil and base of tongue cancers is safe, effective and enables faster recovery times. An estimated 24,000 people in the U.S. are diagnosed with throat cancer each year. View Abstract
Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Cancer Center member Svetomir Markovic, M.D., Ph.D., who holds the academic rank of professor of medicine and associate professor of oncology, was recognized with distinction as the Charles F. Mathy Professor in Melanoma Research View Related
RS5444, being tested in a Phase 1/2 clinical trial to treat anaplastic thyroid cancer, might be useful for treating other cancers. "This is very unusual," says the study's lead investigator, John Copland, Ph.D., a cancer biologist at Mayo Clinic's campus in Florida. "Drugs typically target genes and proteins that are over-expressed and turn them off. We found that RS5444 turns on a valuable tumor suppressor gene. We rarely find a drug that can take a suppressed gene and cause it to be re-expressed." View Abstract 
"There is need for an agent that has a proven ability to reduce colon cancer risk, and this study suggests that enzastaurin could be uniquely effective," says the study's senior investigator, Nicole Murray, Ph.D., of the Department of Cancer Biology. View Abstract
Medical Edge Newspaper A friend of mine was recently diagnosed with tongue cancer. I've never heard of such a thing. Is this common? What is he up against, and how is it treated? View Related
Discovery's Edge Tamoxifen is an anti–estrogen drug that almost halves the return of cancer and reduces the mortality rate by one–third in women with early breast cancer. It is so effective that it has achieved status as somewhat of a miracle drug. However, there is a large group of women who have been taking tamoxifen who might as well have been taking a sugar pill. Three Mayo research teams are collaborating to find the best drugs for these patients. View Related 
Presented at the annual San Antonio Breast Cancer Symposium. "These new results validate our earlier findings," says the study's lead investigator, Matthew Goetz, M.D., an assistant professor of oncology and pharmacology at Mayo Clinic, "and strongly suggest that going forward, postmenopausal patients being considered for tamoxifen therapy should be tested for CYP2D6 before beginning therapy." View Related
Presented at the annual San Antonio Breast Cancer symposium. "Breast cancer is the leading cause of cancer death in women age 25 to 49, and these young patients also have worse overall survival and increased risk of cancer coming back compared to older women, so it is important that we try to understand how the cancer develops and the measures that help prevent it," says the study's lead investigator, Karthik Ghosh, M.D. View Related 
The Gores lab has furthered the understanding of how death receptors trigger the demise of liver cells. View Related 
"Tamoxifen is a good drug, but it looks like aromatase inhibitors may be somewhat better," says James Ingle, M.D., a professor of oncology at Mayo Clinic, who presented the results on behalf of the Aromatase Inhibitors Overview Group (AIOG). Presented at the 2008 San Antonio Breast Cancer Symposium. View Abstract 
Presented at the annual San Antonio Breast Cancer Symposium. "Tens of thousands of women in this country are prescribed tamoxifen for either treatment or prevention of breast cancer, and while it has shown remarkable success, it does not work for a substantial number of patients," says the study's lead investigator, John Hawse, Ph.D. "These findings increase our understanding of tamoxifen and, we hope, could pave the way for improved therapies." View Related
Presented at the annual meeting of the American Society of Hematology (ASH). "These are high remission rates, and they happened quickly," says Martha Lacy, M.D., Mayo Clinic hematologist and lead researcher on the study. Also encouraging, says Dr. Lacy, is that treatment did not cause significant side effects in most patients. View Abstract 
Presented at the annual meeting of the American Society of Hematology (ASH). The study focused on the impact of statin use on outcomes of patients with two most common lymphoma types, diffuse large B-cell lymphoma and follicular lymphoma. Examples of commonly used statins in the U.S. include Lipitor, Zocor, Parvachol, Lescol, Mevacor and Crestor. View Abstract 
Patients who had aggressive surgeries were free of tumor recurrence an average of 15 years after diagnosis If safely removing the entire tumor was not possible, patients survived significantly longer when surgery was followed by radiation therapy. This study is available online in Neuro-Oncology.
Patient Story -- John Fulton Decades after beating bone cancer at Mayo Clinic, John Fulton returned, this time to defeat islet cell cancer. View Related 
Medical Edge Newspaper I was diagnosed with papillary thyroid cancer and had a total thyroidectomy in 2005. I also had modified radical neck surgery in 2007 to remove malignant lymph nodes that were found in my neck. Even though I am on a large dose of levothyroxine and my TSH levels are perfect, I am always exhausted. Are there more blood indicators about my energy level other than TSH? View Related 
Smoking accounts for nearly 90 percent of lung cancer cases MayoClinic.com offers intuitive, easy-to-use tools such as "Symptom Checker" and "First-Aid Guide" for fast answers about health conditions ranging from common to complex; as well as an A-Z library of more than 850 diseases and conditions, in-depth sections on 24 common diseases and conditions, 16 healthy living areas including food and nutrition, recipes, fitness and weight control, videos, animations and features such as "Ask a Specialist" and several consumer blogs. View Related 
"An anti-p120 agent could provide a much-needed double whammy — stop cancer spread and shut down growth at the same time," says the study's lead investigator, Panos Anastasiadis, Ph.D., a Mayo Clinic cancer researcher. Available online in the November issue of the Journal of Cell Biology. View Abstract
Publication: The Journal of Cell Biology -- Nov. 17, 2008 
Mayo Clinic Cancer Center researcher, Diane F. Jelinek, Ph.D., a consultant in the Department of Immunology at Mayo Clinic in Rochester, received the Gene and Mary Lou Kurtz Professorship in Multiple Myeloma Research. View Related 
William C. Rupp, M.D., has been appointed CEO for the Florida campus effective Nov. 21, Mayo Clinic announced today. Rupp currently leads quality projects for Luther Midelfort, part of Mayo Health System, as well as Mayo Clinic. 
Brooke Fridley, Ph.D., has joined Mayo Clinic's Comprehensive Cancer Center as a statistical geneticist to enhance pharmacogenomics studies. View Related 
The second Schulze Symposium was held Friday, November 7, 2008. This event was at the Mayo Clinic in Rochester, Minnesota. 
"We believe this new approach is better for patients because it identifies those who will develop aggressive CLL sooner than later and helps delay need for more toxic treatments," says study lead investigator Clive Zent, M.D., a Mayo hematologist. View Abstract 
The Gail model calculates probabilities that a woman will develop invasive breast cancer during the next five years, and by age 90. "We found that, for the group of women with atypia, the model predicted significantly fewer invasive breast cancers than were actually observed," says Shane Pankratz, Ph.D., Mayo Clinic statistician and a lead investigator in the study. "We also observed that the model was not able to reliably identify the women who were actually at higher risk of developing breast cancer." View Abstract 
MayoClinic.com -- October 2008 MayoClinic.com offers intuitive, easy-to-use tools such as "Symptom Checker" and "First-Aid Guide" for fast answers about health conditions ranging from common to complex; as well as an A-Z library of more than 850 diseases and conditions, in-depth sections on 24 common diseases and conditions, 16 healthy living areas including food and nutrition, recipes, fitness and weight control, videos, animations and features such as "Ask a Specialist" and several consumer blogs. View Related
About 7.4 percent of U.S. women have asthma. The study found that the prevalence of asthma among breast cancer patients with recurrence of their disease as metastases in the lung is two-fold higher than among non-asthmatic women with breast cancer. "If you are a breast cancer patient with asthma, taking your anti-inflammatory inhaled steroids may be more important to you than simply stopping your wheezing" says James Lee, Ph.D., a Mayo Clinic researcher in Arizona and the senior author of the study. View Abstract 
Virtual biopsies will eliminate the need to remove colon polyps that are not cancerous or will not morph into the disease. View Related
"To prevent colorectal cancer deaths, we need an easy-to-use screening tool that consistently finds precancerous polyps," says Dr. Ahlquist. "Stool DNA testing is evolving quickly and may soon fill that need." View Related 
In the October issue of Mayo Clinic Proceedings, two articles authored by Mayo researchers address the issue of how to balance the risks and benefits associated with MM treatments. View Related 
Patient Story -- Aitana Paya Perez Persistant bone cancer hasn't stopped a Spanish student from pursuing her education — and her dreams. View Related 
Mayo Clinic is making big discoveries about minute bits of matter that could revolutionize cancer and heart disease treatment.
Publication: The Journal of Cell Biology -- Sept. 22, 2008 In collaboration with the University of Minnesota 
Study at Mayo Clinic confirms that CT Colonography could serve as screening option "We hope that this additional, less-invasive option for cancer screening will lead more people to get screened and will ultimately result in fewer deaths from colorectal cancer," says C. Daniel Johnson, M.D., principal investigator of the American College of Radiology Imaging Network (ACRIN) National CT Colonography Trial and chair of the Department of Radiology at Mayo Clinic in Arizona. View Related 
Mayo Clinic researchers have discovered that an antibody, previously identified as a treatment for cancer, also diminishes the overactive immune responses in asthma.
The Mayo Clinic team proposed patient-centered processes that should occur prior to, during and after surgery to assure the likelihood of best surgical outcomes. View Related 
Cancer Center member Larry Pease, Ph.D., chair of the Department of Immunology and a professor in the Departments of Immunology, and Biochemistry and Molecular Biology, received the Gordon H. and Violet Bartels Professorship in Cellular Biology. View Related 
Patient Story -- Howard Lloyd Nonmelanoma skin cancer returns twice, but can't keep a retired Navy officer from running his life. View Related 
Potentially, this vaccine could be used as a complementary tool with tamoxifen, a widely used estrogen therapy used as a temporary post-treatment approach to prevent the return of tumors. Breast cancer is second only to lung cancer as a killer of women. In 1998-2002, according to the American Cancer Society, 95 percent of new cases and 97 percent of deaths occurred in women 40 and older in the United States. However, early diagnosis and treatment have led to increasing survival rates in the last 25 years. There are more than two million breast cancer survivors in the United States today. Breast cancer is second only to lung cancer as a killer of women. In 1998-2002, according to the American Cancer Society, 95 percent of new cases and 97 percent of deaths occurred in women 40 and older in the United States. However, early diagnosis and treatment have led to increasing survival rates in the last 25 years. There are more than two million breast cancer survivors in the United States today. View Related 
Patient Story -- Milo Pietz Lung cancer surgery at Mayo Clinic returns South Dakota singer to an active life. View Related 
Implications of aging and self-tolerance on the generation of immune and antitumor immune responses.
Publication: Cancer Research -- July 1, 2008 
Publication: Cancer Research -- June 15, 2008 
Patient Story -- Jim Turner Cancer treatment and heart surgery at Mayo Clinic helped Jim Turner live actively in retirement. View Related 
Technique combining chemo-radiation and surgery to be presented at ISIORT conference A study of patients with locally unresectable or borderline resectable pancreas cancer has indicated that the disease survival rates can potentially be doubled by aggressively combining radiation, chemotherapy and surgery. View Related 
Mayo Clinic study reveals longer survival times following staging procedure Pancreatic cancer, even when diagnosed early, often has a poor prognosis. Signs and symptoms may not appear until the cancer is quite advanced and surgical removal is not possible. Pancreatic cancer, as a result, is a leading cause of death. View Related 
Mayo Clinic Researchers Find Common Gene Disorder Doubles Risk of Lung Cancer, Even Among Nonsmokers
Mayo Clinic researchers have found that carrying a common genetic disorder doubles the risk of developing lung cancer in smokers and nonsmokers. View Abstract 
A probe so sensitive that it can tell whether or not a cell living within the human body is veering towards cancer development may revolutionize how future colonoscopies are done, say researchers from the Mayo Clinic in Jacksonville, Fla. View Related
This release is being sent in a social media format, in conjunction with the National Cancer Institute, part of the NIH. A new study being presented at the American Society of Clinical Oncology meeting in Chicago (Abstract #4020), may change treatment practice in about 25 percent of patients with colon cancer and is the basis for proposed changes to the way colorectal cancers will be staged. View Related
Study to be presented at the American Society of Clinical Oncology annual meeting The number of women undergoing mastectomy (total breast removal) for early-stage breast cancer has increased in the last three years at Mayo Clinic in Rochester. The increase follows a steady decline during the prior seven years. View Related 
Study to be presented at the American Society of Clinical Oncology annual meeting Adding a second monoclonal antibody drug to chemotherapy looks promising for treatment of diffuse large B-cell lymphoma, according to Mayo Clinic researchers working with the North Central Cancer Treatment Group (NCCTG) (http://ncctg.mayo.edu/). View Related 
Findings will enable patients with advanced colon cancer to complete treatment with fewer side effects; study to be presented at the American Society of Clinical Oncology Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of neurological side effects (neurotoxicity). View Related 
Study to be presented at the American Society of Clinical Oncology annual meeting Mayo Clinic researchers and collaborators say they have conclusively demonstrated that a substantial subset of colon cancer patients should not receive chemotherapy because it provides no clinical benefit, and actually may reduce survival time. View Related
Study to be presented at the American Society of Clinical Oncology annual meeting Patients who feel better live longer, say Mayo Clinic researchers, working with the North Central Cancer Treatment Group (NCCTG). View Related 
Increased expression of SULF2 enhances cancer cell growth and migration, whereas decreased expression reduces both. Deadly and difficult to treat, liver cancer has long resisted attempts by researchers to develop ways to prolong life and prevent recurrence. But Mayo Clinic Cancer Center, in collaboration with the National Cancer Institute, reports in the April issue of Hepatology that the protein sulfatase 2 (SULF2) may provide one of the keys needed to begin the design of new therapies. View Abstract
Patient Story -- Jasper Johnikin Innovative technology and surgical expertise helped Mayo Clinic physicians save kidney cancer patient Jasper Johnikin's kidney — and his life. View Related 
Mayo Clinic is collaborating with the University of Minnesota to identify tell-tale genes that would reveal cancerous tumors in the brain. "Already, we have identified almost two dozen primary brain tumors that appear to have been induced by a gene mutation that we introduced into our mouse models," said Robert Jenkins, M.D., Ph.D., of Mayo Clinic. While that is a remarkable discovery, he said, the tumors must be more fully studied to determine precise, genetically relevant information. View Related
What if you could prevent Barrett's esophagus or stop its progression to esophageal cancer? And, while you were working on that, what if you could develop therapies that replace the standard treatment with a much less debilitating treatment than removal of the esophagus? View Related 
Mouse study shows dopamine blocks tumor-feeding blood vessels "Sometimes new drugs may not be the answer. We looked instead at a novel use for an established product and have found very promising results," says Mayo Clinic oncology researcher Sujit Basu, M.D., Ph.D. View Related 
CT colonography, also known as virtual colonoscopy, underwent rigorous studies at Mayo Clinic for more than 10 years, while the stool DNA test was conceived and developed by Mayo Clinic researchers. View Related 
The research team discovered that women whose atypia tissue expressed COX-2 enzymes were more likely to develop breast cancer subsequently, and that the more the enzyme expressed, the higher the risk. View Abstract 
Discovery's Edge Disease should not be an eventual part of aging, yet something happens as we near retirement age that makes a variety of cancers far more likely. Joseph Lustgarten, Ph.D., and his colleagues at Mayo Clinic are focusing on changes in the immune system, trying to find a connection, a cause, and then a therapy.
News in Minnesota Yuichi Machida, Ph.D., of the University of Virginia, will join Mayo Clinic's Division of Oncology Research in May. 
ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study) "There have been major improvements in the management of patients with early breast cancer in the last few years, so this new study builds on this knowledge and sets an example of the new era: good science, good worldwide collaboration," said Edith Perez, M.D., an oncologist in the North Central Cancer Treatment Group (NCCTG) at Mayo Clinic in Jacksonville, Fla., who will lead the study for TBCI. View Related
Agreement strengthens relationship and spawns new scientific collaborations "TGen takes seriously our commitment to work toward helping patients with cancer and other disorders. This announcement is another mechanism allowing TGen and Mayo faculty to work bi-directionally in a more seamless fashion," said Jeffrey Trent, Ph.D., TGen's president and scientific director. View Related 
Study lays foundation for future development of effective treatments "This model helps us understand the genetic properties that lead to multiple myeloma and provides a framework for developing better therapies," said Leif Bergsagel, M.D., a Mayo Clinic physician and lead investigator for the study. "We will now be able to test new treatments on models." View Abstract
Mayo Clinic Cancer Center IDs two signatures predicting survival The team found two survival-related 50-gene signatures, one for each of the two cancer types. These were nonoverlapping and largely unique in gene content compared to previously identified predictive gene expression signatures for lung cancer developed by other researchers. View Related 
Named professorships at Mayo Clinic represent the highest academic distinction for a faculty member. Sandra Gendler, Ph.D., was named the David F. and Margaret T. Grohne Research Professor in Therapeutics for Cancer Research. Richard Vile, Ph.D., a consultant in the Department of Molecular Medicine and Department of Immunology at Mayo Clinic Rochester, was honored with The Richard M. Schulze Family Foundation Professorship.
Research into the B7 molecules has been a "family affair" at Mayo. Many Mayo immunologists have joined together to tackle various aspects of their function and behavior and have discovered how they function. 
Using two different endoscopes together is better than using one to stage lung cancer, and is also much more precise and less invasive than the surgical method now most commonly used. "Both scopes together found more malignant lymph nodes than did the use of a single endoscope," says the study's lead investigator, Michael Wallace, M.D., M.P.H., Professor of Medicine at Mayo Clinic, Jacksonville, Fla. "Doing both procedures at once takes little time, requires only a mild sedative, and patients go home the same day." View Abstract
Sound waves may help early detection of heart failure caused by Trastuzumab "Breast cancer is the second most common form of cancer in women, and the leading cause of death," says Bijoy K. Khandheria, M.D., chair, Mayo Clinic Cardiovascular Services, researcher and co-investigator of the study. "Anticancer drugs like Trastuzumab have substantial benefits, but in some patients the anticancer drug cross-reacts with the heart muscle. Therefore, methods to detect and halt heart muscle damage is therefore urgently required." View Abstract 
Patient Story -- Tom Sherrard Radiation therapy and surgery put a stop to aggressive anaplastic thyroid cancer. View Related 
Discovery's Edge "When we examined human breast tissue we were blown away by how dramatic and obvious the centrosome abnormalities were in the tumors," says Jeffrey Salisbury, Ph.D. "And that was literally on day one." View Related 
News from Rochester, Minn. Stereotactic radiosurgery uses precisely focused radiation to treat tumors and other abnormal growths in the brain. View Related 
Study's authors recruit patients for a clinical trail, another step in this ongoing research "We are now quite convinced that in most patients with pancreatic cancer the diabetes is caused by the cancer and not the other way around," says Suresh Chari, M.D., a Mayo Clinic gastroenterologist and the study's lead author. "Our next step is to identify a biomarker for pancreatic cancer-induced diabetes in order to screen patients with new-onset diabetes for early pancreatic cancer and provide surgical treatment as quickly as possible." View Abstract
Medical Edge Radio For more information on lung cancer treatment at Mayo Clinic, visit http://www.mayoclinic.org/lung-cancer. Read Script
Removing the entire kidney from younger patients with small kidney tumors may lead to decreased overall survival. "For patients with small kidney tumors, removal of the entire kidney may be associated with long-term consequences that we did not previously recognize when compared to removal of just the tumor," says the study's lead author, R. Houston Thompson, M.D., a Mayo Clinic urologist currently serving a fellowship at Memorial Sloan-Kettering Cancer Center. View Related
Collaboration aims to find high-tech solutions for quicker diagnosis, better treatments "This facility will allow us to explore projects in medical imaging and radiology that can provide faster and better information for our physicians, and in turn, improved treatments for our patients," said Bradley Erickson, M.D., Ph.D., head of Mayo's Radiology Informatics Lab. View Related
Patient Story -- Karen Gibson Surgery at Mayo Clinic in Jacksonville to remove a renal cell tumor prompted this Jacksonville mom to participate in a study to help unravel the mystery surrounding her disease. View Related
Presented at the American Society of Hematology's 2007 meeting "In this study we were hoping to find that a lower dose of steroids would be just as effective," says Vincent Rajkumar, M.D., Mayo Clinic Cancer Center hematologist and lead investigator of the study. "We were surprised to find that the regimen with high-dose steroids actually was decreasing survival, besides contributing to increased side effects." View Related
Phase 2 Consortium clinical trial shows promising results Presented by the study's primary investigator, Keith Bible, M.D., Ph.D., at the Molecular Targets and Cancer Therapeutics International Conference, a jointly-sponsored symposium of the American Association for Cancer Research, National Cancer Institute and the European Organization for Research and Treatment of Cancer. "We are encouraged by the interim results of this trial," says Dr. Bible, a medical oncologist and researcher at Mayo Clinic. "Platinum-resistant ovarian cancer responds poorly to traditional therapies, and we've been working toward developing more effective treatments for this disease. This combination looks very promising." View Abstract 
Up to 30 percent of patients with colon and rectal cancer may develop a bowel obstruction View Related 
Publication: Cancer Research -- Sept. 15, 2007
Radiology researchers at Mayo Clinic have invented a diagnostic imaging tool with remarkable capabilities. It's called Magnetic Resonance Elastography or MRE. MRE can measure elasticity - detecting abnormal hardening of liver tissue - sparing some patients the need for a biopsy and allowing physicians to begin intervention aimed at treating their disease before it progresses to cause irreversible damage. View Related 
Publication: Journal of Clinical Oncology -- June 4, 2007 A Final Report of the AIO Colorectal Study Group (Association of Medical Oncology within the German Cancer Society) View Related 
Mayo Clinic Cancer Center had researchers from many disciplines presenting more than 60 oral abstracts and dozens of posters, also educational sessions and other special events throughout the 2007 ASCO program, June 1-5. View Related
Multiple myeloma is the second most common blood cancer in the United States after lymphoma, yet no new treatments have been developed in a generation. "Our goal is to deliver individualized care based on the latest genomic information and drugs available," Dr. Lief Bergsagel says. "We intend to find ways to offer the right drug to the right patient each time. And we're set to be among the first to make it happen for patients with multiple myeloma." View Related 
Osteoporosis was not even considered a disease before Mayo Clinic's 1980s groundbreaking epidemiology studies. Funded by a $1.2 million per year NIH Program Project grant, the osteoporosis research team is also taking their research to the genetic and molecular levels to study the physiology of bone metabolism in an aging population. Their studies investigate the TGF-beta-Inducible Early Gene (TIEG) gene's role in bone and skeletal disorders such as osteoporosis and breast cancer metastasis to the bone. View Related 
Clinical Trial Stopped Early Because of Very Positive Results in Treatment Arm A large clinical trial has been halted early because gastrointestinal stromal tumor patients taking Gleevec after surgery did so much better than patients who did not take the drug. The Phase III trial was conducted by the American College of Surgeons Oncology Group (ACOSOG), an NCI Cooperative Group, in collaboration with Cancer and Leukemia Group B, South West Oncology Group, Eastern Cooperative Oncology Group, and National Cancer Institute of Canada Clinical Trials Group. ACOSOG is led by Group Co-chairs Dr David Ota of the Duke Clinical Research Institute, the site of the operations office, and Dr Heidi Nelson of the Mayo Clinic Cancer Center, the site of the Biostatistics. View Related 
Publication: Mayo Clinic Proceedings -- April 2007 Critical to the clinical management of a patient with malignant melanoma is an understanding of its natural history. As with most malignant disorders, prognosis is highly dependent on the clinical stage (extent of tumor burden) at the time of diagnosis. The patient’s clinical stage at diagnosis dictates selection of therapy. We review the state of the art in melanoma staging, prognosis, and therapy. View Related 
Publication: Journal of Clinical Oncology -- Apr. 1, 2007 Results of a Prospective Phase III North Central Cancer Treatment Group Clinical Trial View Related 
Publication: Journal of Supportive Oncology -- March 2007 North Central Cancer Treatment Group in conjunction with Mayo Clinic Cancer Center View Related 
Publication: Mayo Clinic Proceedings -- March 2007 Mammography added little information to the initial patient evaluation. Breast cancer may be suspected by the presence of a dominant mass. Gynecomastia can be predicted on the basis of the patient's symptoms or preexisting condition. Patients with suspicious findings on examination warrant appropriate clinical management regardless of mammographic findings. Mammography in men may be of benefit only for image guidance of percutaneous biopsy of a suspicious mass. View Related 
Publication: Mayo Clinic Proceedings -- March 2007 The purpose of this consensus is to offer a simplified, evidence-based algorithm of decision making for patients with newly diagnosed myeloma. In cases in which evidence is lacking, our team of 18 Mayo Clinic myeloma experts reached a consensus on what therapy could generally be recommended. The focal point of our strategy revolves around risk stratification. Although a multitude of risk factors have been identified throughout the years, including age, tumor burden, renal function, lactate dehydrogenase, beta2-microglobulin, and serum albumin, our group has now recognized and endorsed a genetic stratification and patient functional status for treatment. View Related 
Publication: Mayo Clinic Proceedings -- March 2007 In the first part of this 2-part review, we discuss epidemiology, risk factors, screening, prevention, and diagnosis of malignant melanoma. Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment. View Related 
Death Rates for Smokers Remain the Same Despite Early Diagnosis An international study looking at computed tomography (CT) to screen current or former smokers for lung cancer found that the screening did not reduce death. Researchers from Mayo Clinic Cancer Center, along with the Instituto Tumori, Milan, Italy; and Memorial Sloan-Kettering and Moffitt Cancer Centers collaborated to report the findings, which are published in the Mar. 7, 2007, issue of the Journal of the American Medical Association (JAMA). View Related 
Publication: Cancer -- Feb. 15, 2007 Information gleaned from the single-item Uniscale assessment was comparable to that gleaned from multiple-item global measures. There was moderate agreement between QOL and AE. A 10-point decline in QOL occurred earlier than Common Toxicity Criteria AE reporting. This suggests the need for inclusion of a QOL instrument in lung cancer clinical trials.
Publication: Journal of Clinical Oncology -- Jan. 20, 2007 North Central Cancer Treatment Group View Related 
Publication: Mayo Clinic Proceedings -- Dec. 2006 Optimism was associated with a higher QOL in survivors of thyroid cancer compared with survivors of head and neck cancer. After adjusting for age, sex, and disease stage, optimism was not associated with QOL for survivors of head and neck cancer. Optimism was more associated with the mental rather than physical QOL subscales. 
Publication: Mayo Clinic Proceedings -- Dec. 2006 Discontinuation of urine studies and reliance on a diagnostic algorithm using only serum studies (protein electrophoresis, immunofixation, and free light chain quantitation) missed 2 (0.5%) of the 428 monoclonal gammopathies with urinary monoclonal proteins, and these 2 cases required no medical intervention. View Related
Publication: Journal of Clinical Oncology -- Dec. 1, 2006 North Central Cancer Treatment Group View Related
Publication: Radiology -- Nov. 2006
Publication: Cancer -- Oct. 15, 2006 The key to long-range improvement in cancer morbidity and mortality in American Indian/Alaska Native communities lies in building infrastructure to support strong partnerships that enable culturally appropriate, community-based participatory research. View Related 
Publication: Cancer Research -- Oct. 15, 2006 Combined deletion of chromosomes 1p and 19q is associated with improved prognosis and responsiveness to therapy in patients with anaplastic oligodendroglioma. Jenkins et al. used stem cell culture techniques to recover a t(1;19)(q10;p10) from an oligodendroglioma, suggesting that the translocation likely mediates the combined 1p and 19q deletions. The authors then developed an interphase fluorescence in situ hybridization (FISH) strategy to detect the t(1;19) in paraffin-embedded tumors. Using gliomas from patients enrolled on NCCTG trials, the FISH test demonstrated that the translocation is highly prevalent in oligodendrogliomas and is associated with superior survival. View Related 
Publication: Cancer Research -- Oct. 15, 2006 To understand better the underlying mechanisms by which tumor cells are resistant to CTL-mediated apoptosis, Yang et al. used a human model of B-cell non-Hodgkin’s lymphoma (B-cell NHL) to show that intratumoral Treg cells inhibit the proliferation and granule production of activated autologous infiltrating CD8+ T Cells. View Related
Publication: Science -- Oct. 13, 2006 Biochemistry and Molecular Biology department researchers report that a protein that initiates a “quality control check” during cell division also directs cell death for those cells damaged during duplication. View Related 
Publication: Journal of Cell Biology -- Sept. 25, 2006 p120 catenin is a protein known for as a key cell adhesion component. New findings by Mayo Clinic Cancer Center researchers at Jacksonville show that p120 also works to break cells apart from one another and promote cellular movement when tumors metastasize. The study illuminate a very early step involved in metastasis, the spread of cancer that makes the disease difficult to treat, and suggests that a future designer drug might be able to block the beginning of this dangerous process – or stop it once it starts. View Related
Publication: Journal of Clinical Oncology -- Aug. 20, 2006 North Central Cancer Treatment Group along with Southwest Oncology Group View Related
Publication: Cancer -- Aug. 15, 2006 Early and complete extended partial cystectomy, including umbilectomy, is critical to the survival of patients with UrC. The authors recommend using the Mayo staging system in future studies because of its simplicity. The current results indicated that the most important predictors of prognosis were tumor grade and surgical margin status. View Related 
Publication: Cancer -- Aug. 15, 2006 Pooled Analysis of North Central Cancer Treatment Group Trials. In addition to the widely accepted prognostic factors of PS, BMI, and disease stage, both of the readily available laboratory parameters of Hgb level and WBC count were found to be significant prognostic factors for OS and TTP in patients with advanced-stage NSCLC. The authors' prediction equation can be used to evaluate the benefit of a treatment in Phase II trials by comparing the observed survival of a cohort with its expected survival by using the patients' own prognostic factors in place of comparisons with historic data that may have substantially different baseline patient characteristics. View Related
Publication: Mayo Clinic Proceedings -- Aug. 2006 These guidelines were developed in the Interest of patient safety and will be reexamined as new data emerge regarding risks and benefits. View Related 
Publication: Mayo Clinic Proceedings -- Aug. 2006 Our experience indicates that with appropriate technique, primary surgical treatment may offer benefit to selected patients with osteonecrosis of the jaw. View Related 
Publication: Journal of Clinical Oncology -- Aug. 1, 2006 A companion study to the National Cancer Institute of Canada Clinical Trials Group study MA.17 View Related 
Publication: Cancer -- July 1, 2006 Mononuclear cell infiltration is associated with death from renal cell carcinoma even after multivariate adjustment. Routine documentation of mononuclear cell infiltration is recommended during the pathologic assessment of renal cell carcinoma. View Related
Publication: Journal of Clinical Oncology -- July 1, 2006 North Central Cancer Treatment Group View Related 
Publication: Journal of Clinical Oncology -- June 20, 2006 North Central Cancer Treatment Group clinical trial View Related 
Publication: Cancer -- June 15, 2006 The current results confirmed that there were changes in the prevalence of Gleason grades on radical retropubic prostatectomy specimens between 1989 and 2001. A chronological change in pathologic grading classification is suggested by evolving prognostic implications, which must be accounted for when comparing outcomes from different eras. View Related
Publication: Mayo Clinic Proceedings -- June 2006 The results suggest that providing women scheduled for screening mammograms with physician-approved educational material before their appointment significantly increases knowledge about screening mammography, risks and benefits, and possible follow-up. View Related
Publication: Mayo Clinic Proceedings -- May 2006 Pulmonary resection in patients with stage I or stage II small cell lung cancer is safe with low mortality and morbidity. Curative resection is associated with long-term survival in early stage small cell lung cancer in some patients and should be considered in selected patients. View Related 
Medical Edge Television Not long ago kids had to have their legs amputated to get rid of rotationplasty. But now doctors at Mayo Clinic are performing a surgery that allows kids to regain use of their leg, even after part of it has been removed.
Medical Edge Television This story focuses on one child who received a transplant from an unrelated donor. Her story highlights how treatment for childhood diseases such as aplastic anemia and leukemia has improved dramatically in recent years.
Publication: Journal of Clinical Oncology -- Dec. 20, 2005 Results of a pooled analysis from the North Central Cancer Treatment Group View Related 
Publication: Journal of Clinical Oncology -- Dec. 20, 2005 A North Central Cancer Treatment Group Phase II study View Related 
Publication: Journal of Clinical Oncology -- Dec. 1, 2005 Individual patient data from 20,898 patients on 18 randomized trials: North Central Cancer Treatment Group View Related
Publication: Journal of Clinical Oncology -- Aug. 10, 2005 A North Central Cancer Treatment Group Study View Related
Gemcitabine and ISIS-2503 for patients with locally advanced or metastatic pancreatic adenocarcinoma
Publication: Journal of Clinical Oncology -- Dec. 15, 2004 North Central Cancer Treatment Group clinical trial View Related 
Publication: Journal of Clinical Oncology -- Sept. 15, 2004 North Central Cancer Treatment Group clinical trial View Related 
Publication: Journal of Clinical Oncology -- Aug. 15, 2004 North Central Cancer Treatment Group -- intergroup clinical trial View Related
Publication: Journal of Clinical Oncology -- June 15, 2004 North Central Cancer Treatment Group with National Cancer Institute of Canada View Related
Publication: Journal of Clinical Oncology -- May 15, 2004 North Central Cancer Treatment Group pooled results with US Gastrointestinal Intergroup and the National Surgical Adjuvant Breast and Bowel Project View Related
Publication: Journal of Clinical Oncology -- May 1, 2004 North Central Cancer Treatment Group study View Related
The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma
Publication: Blood -- Oct. 1, 2003 View Related
|
LEGAL RESTRICTIONS AND TERMS OF USE APPLICABLE TO THIS SITE
Use of this site signifies your agreement to the terms of use.
© 2012 Mayo Foundation for Medical Education and Research. All rights reserved.
